AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, is set to initiate a Phase III study for its PD-1xTIGIT bispecific antibody (BsAb) rilvegostomig in combination with chemotherapy for patients with biliary tract cancer (BTC) following surgical resection. The double-blind, placebo-controlled, global trial aims to assess the efficacy and tolerability of the treatment in approximately 750 patients who are at risk of disease recurrence.
The primary endpoint of the study will be recurrence-free survival (RFS), which is measured from the time of randomization until the date of radiological recurrence or death from any cause.
According to the public data, AstraZeneca is in competition with several Chinese drug developers who also have PD-1xTIGIT BsAb candidates in clinical trials. These include Zhejiang Huahai Pharmaceutical (SHA: 600521), Shanghai Henlius Biotech (HKG: 2696), Shandong Buchang Pharmaceuticals (SHA: 603858), and Suzhou Zelgen Biopharmaceuticals (SHA: 688266).- Fineline.com
